

Improving antibody-based cancer therapeutics through glycan engineering

Xiaojie Yu^{1,*}, Michael J.E. Marshall¹, Mark S. Cragg¹, and Max Crispin^{2,3*}

¹The Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, SO16 6YD, UK.

²Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, United Kingdom

³Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, United States

*Correspondence: max.crispin@bioch.ox.ac.uk, x.yu@soton.ac.uk

Abstract

Antibody-based therapeutics have emerged as a major tool in cancer treatment. Guided by the superb specificity of the antibody variable domain, they allow the precise targeting of tumour markers. Recently, eliciting cellular effector functions, mediated by the Fc domain, have gained traction as means by which to generate more potent antibody therapeutics. Extensive mutagenesis studies of the Fc protein backbone has enabled the generation of Fc variants that more optimally engage the Fc γ -receptors (Fc γ R) known to mediate cellular effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and cellular phagocytosis (ADCP). In addition to the protein backbone, the homodimeric Fc domain contains two opposing N-linked glycans, which represent a further point of potential immunomodulation, independent of the Fc protein backbone. For example, a lack of core fucose usually attached to the IgG Fc glycan leads to enhanced ADCC activity, whereas a high level of terminal sialylation is associated with reduced inflammation. Significant growth in knowledge of Fc glycosylation over the last decade, combined with advancement in genetic engineering, has empowered glyco-engineering to fine-tune antibody therapeutics. This has culminated in the approval of two glyco-engineered antibodies for cancer therapy: the anti-CCR4 mogamulizumab approved in 2012 and the anti-CD20 obinutuzumab in 2013. We discuss here the technological platforms for antibody glyco-engineering, and review the current clinical landscape of glyco-engineered antibodies.

Key Points

Antibody glycosylation can significantly influence clinical efficacy.

Design and selection of antibody glycoforms offers a route to enhanced therapies.

1 Introduction

Since the approval of rituximab in 1997, the first monoclonal antibody (mAb) approved for the treatment of cancer, antibody-based therapies have revolutionized the field of clinical oncology¹⁻². The success of rituximab has driven an explosion of interest in antibody therapeutics and fostered the desire to identify other therapeutic targets and to augment antibody efficacy through protein engineering³. As of June 2016, 24 mAbs, mostly human IgG-based, had been approved by the Food and Drug Administration (FDA) for the treatment of solid or haematological tumours⁴⁻⁶.

Antibodies used in cancer treatment can be broadly classified into two categories based on their target type. The conventional ‘direct targeting’ class of cancer antibodies, comprising the majority of approved antibodies such as the anti-CD20 rituximab and anti-Her2 trastuzumab, target tumour cells by direct engagement of either lineage specific antigens (e.g. CD20), tumour neoantigens (e.g. glycans) or overexpressed oncogenic antigens (e.g. EGFR). After antibody engagement, the tumour cells are selectively depleted via various routes such as signalling-induced apoptosis or Fc-mediated complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP), depending on the nature of the antibody, target antigen and epitope⁷. The second class of anti-cancer antibodies, so-called immunomodulatory mAbs do not directly engage the tumour cells but rather target receptors on cells of the host immune system in an attempt to stimulate increased activity, principally through cytotoxic CD8+ T cells⁸⁻¹⁰. Antibody immunotherapy of this type came to the spotlight when the first immune “checkpoint blocker” anti-CTLA4 mAb ipilimumab received approval to treat advanced melanoma, following the demonstration that it could significantly improve the prognosis for a proportion of patients with this aggressive malignancy¹¹.

Despite the evident clinical efficacy of anti-cancer antibodies, their modes of action are often incompletely understood. It is generally accepted that for the conventional direct-targeting antibodies, the variable domain targets the tumour-selective antigen, conferring specificity, while the Fc domain mediates the elimination of tumour cells via the host immune system¹²⁻¹³. However, antibodies designed to effectuate through the blockade of signal transduction, such as the anti-Her2 trastuzumab, may also work in part through the same mechanisms and moreover could attain additional functionality through Fc engineering. The relative contribution of the variable and Fc domains to the immunomodulatory mAbs is currently unclear. For example, agonistic anti-CD40 mAbs, which stimulate host antigen-presenting cells to potentiate an immune response against the tumour by activating CD40, a tumor necrosis factor receptor (TNFR), were also found to require the Fc domain for therapeutic efficacy¹⁴. However, the specific FcγR required was shown to be entirely different to that engaged by direct targeting mAb in several pre-clinical models¹⁴⁻¹⁸. Moreover, isotype-switching to the less common IgG2 obviated the need for the Fc domain, resulting in Fc-independent agonistic activity^{15, 19}. Similar paradigms have been seen with other TNFR targets, demonstrating that the Fc and its interaction with FcγR are critical in delivering therapeutic responses for many antibody classes^{15, 20}.

2 Rationale for antibody glyco-engineering

2.1 The Fc-FcγR engagement

The general requirement of the IgG Fc domain for a fully functional cancer antibody has prompted the use of Fc engineering to improve the efficacy of mAb effector functions. The IgG Fc engages a set of FcγRs that are expressed predominantly on immune effector cells to mediate effector functions²¹⁻²². These FcγRs are categorized into either activatory or inhibitory based on their intracellular signalling motif. The human activatory FcγRs, FcγRI, FcγRIIa, FcγRIIc, and FcγRIIIa, contain an intracellular activatory immunoreceptor tyrosine-based activation motif (ITAM) signalling motif within the cytoplasmic domain of the receptor (FcγRIIa and IId) or on the associated FcRγ chain; while the sole inhibitory FcγRIIb contains an inhibitory immunoreceptor tyrosine-based inhibitory motif (ITIM) within its cytoplasmic domain²²⁻²³. Humans additionally express another FcγR, FcγRIIb, which is highly homologous to FcγRIIIa in its extracellular domain but contains no transmembrane or intracellular regions, instead being anchored to the membrane through a glycosphosphoinositol anchor and expressed solely on neutrophils²⁴. Mice express 4 homologs: 3 of which (FcγRI, FcγRIII and FcγRIV) are activatory while FcγRIIb is inhibitory, as in humans²⁵.

In humans, the activatory FcγRIIIa is widely regarded to be the most important for delivering Natural Killer (NK) cell-mediated ADCC as FcγRI and IId are not expressed on these cells and FcγRIIc is only expressed in a relatively small proportion of people due to the presence of a stop codon²⁶. Furthermore, a functional polymorphism present within FcγRIIIa at position 158, which alters the receptor's affinity for IgG1 and 3, has been reported to significantly affect the clinical response to rituximab therapy²⁷⁻²⁸. The importance of effective Fc-FcγR engagement for anti-tumour antibody efficacy has led to exhaustive Fc mutagenesis studies, which have identified residues critical for FcγR engagement and also enabled the generation of Fc variants that selectively engage specific FcγRs²⁹. Many of these characterisations were carried out in vitro in systems where the mAb of interest represents the dominant antibody, which fails to recapitulate the in vivo environment where a high concentration of endogenous serum IgG (approximately 10 mg/ml) will compete with exogenously administered therapeutic antibodies for FcγR engagement³⁰. Weakening such intrinsic endogenous IgG-FcγR interaction, through the inactivation of serum IgG Fc, a strategy termed "receptor refocusing", could effectively improve the activity of therapeutic mAbs³¹.

2.2 Antibody glycosylation and FcγR engagement

Besides protein mutagenesis, antibody Fc glycosylation could also significantly modulate the Fc-FcγR interaction, through its conserved N-linked oligosaccharide attached to the Asparagine 297³². Antibody N-glycosylation occurs co-translationally in the lumen of the ER and initially follows a highly conserved and well-delineated pathway involving the transfer of a large pre-assembled glucosylated oligomannose-type oligosaccharide. As the protein transits from the ER and through the Golgi apparatus, different glycan transferases and glycosidases, add or remove different monosaccharides to create a diverse range of oligosaccharides differing in size and complexity. The diversity of IgG Fc glycoforms, like the myriads of other glycoproteins, arises from both the cellular environment and the intrinsic three-dimensional structure of the protein. However, despite the potential for considerable chemical heterogeneity IgG Fc glycosylation is characterized by a predominant population of glycans displaying limited processing of terminal residues giving rise to a characteristic fingerprint of glycoforms with partial galactosylation.

Our current understanding of how the Fc glycan regulates antibody function has undergone a recent transition from being a simple structural support to a major immunomodulating agent. Early evidence supporting the importance of Fc glycan came from in vitro studies where IgG deglycosylation abrogated its effector functions³³⁻³⁵. Since then, divergent activities of various IgG glycoforms, whether naturally occurring or engineered, have firmly established its immune-modulatory potential. The first clinical association was noted in rheumatoid arthritis patients, where a lack of terminal galactose in the IgG Fc glycoforms was correlated with disease induction, suggesting a pro-inflammatory role of agalactosylated glycoforms³⁶. This was further supported by reports that the typical period of symptom remission noted during pregnancy was associated with a decrease in the level of agalactosylated IgG glycans³⁷⁻³⁹. Furthermore, HIV controllers who demonstrate better viral containment exhibit globally more agalactosylated IgG glycoforms⁴⁰. In contrast to agalactosylation, more recently, it was described that Fc bearing terminal α 2,6-linked sialic acids possess general anti-inflammatory effects in vivo⁴¹⁻⁴² and this effect may be influenced by the fucosylation status⁴³.

Besides galactose and sialic acid, the monosaccharide that has the most explicit influence on antibody therapeutics is the core fucose; fucose α 1,6-linked to the protein-proximal GlcNAc residue. Engineered IgG Fc that lacks the core fucose was initially found to display significantly enhanced ADCC through improved engagement with Fc γ RIIIa, an observation reproduced by many independent laboratories since⁴⁴⁻⁴⁸. The crystal structures of fucosylated Fc in complex with the human Fc γ RIIIa elegantly illustrate how the receptor glycan clashes with the antibody fucose; a conflict which is resolved with afucosylated Fc, explaining its enhanced affinity⁴⁸⁻⁴⁹ (Figure 1).

2.3 Fc engineering and immunogenicity

The human immune system is well known for its ability to recognise and reject foreign entities, through both humoral and cell-mediated response. Therefore, it is not surprising that, for example, patients receiving the chimeric mouse/human anti-CD20 rituximab can elicit a human anti-mouse antibody immune response directed against the remaining mouse framework regions upon first exposure, which then complicates repeated use due to hypersensitivity reactions and reduced mAb half-life⁵⁰⁻⁵¹. Site-directed mutagenesis of native antibody Fc domains, which dominates the current landscape of Fc engineering, could therefore potentially spawn Fc neo-immunogens, even though there is a lack of such reports in the current literature. On the contrary, Fc glyco-engineering, predicated on the appendage of defined endogenous glycoforms, may in fact circumvent immunogenicity.

Nevertheless, for mAbs produced in non-human cell-lines, the impact of glycosylation on antibody immunogenicity has been recognised as a potential issue. For example, the anti-epidermal growth factor receptor (EGFR) cetuximab, which contains both Fab and Fc N-linked glycans, was found to contain the non-human glycan structure galactose- α 1,3-galactose in its Fab glycans when produced in mouse Sp2/0 cells⁵²⁻⁵³. Humans express natural IgG reactive towards galactose- α 1,3-galactose, and it was discovered that patients with high levels of pre-existing anti-galactose- α 1,3-galactose IgE, a class typically associated with allergy, displayed a hyper-sensitivity reaction to cetuximab⁵⁴⁻⁵⁵. Interestingly, the same cetuximab-specific IgE antibodies isolated from patients that had demonstrated hypersensitivity did not react with cetuximab produced in CHO cells which naturally lack α 1,3-

galactosyltransferase activity. This further highlights the importance of antibody glycosylation and the choice of appropriate host cell line for therapeutic antibody production.

Given the immunomodulatory capacity of Fc glycan, glyco-engineering presents a viable path besides protein engineering to optimize the therapeutic activity of anti-tumour antibodies. As fucose engineering dominates the current portfolio of tumour-targeting antibodies, we focus this review on platforms for fucose engineering, and discuss fucose-engineered antibodies. It is however important to note that other means of glyco-engineering could prove equally useful in the future, especially for the immunomodulatory antibodies whose glycoforms remain largely unexplored.

3 Platforms for fucose engineering

IgG Fc with a low level of core fucose engages FcγRIIIa and FcγRIIIb with higher affinity and therefore leads to enhanced ADCC and ADCP⁵⁶⁻⁵⁸. This finding had triggered extensive research into methods for generating low fucose or fully afucosylated IgG. Several major methodologies have emerged to be applicable in making therapeutic antibodies.

3.1 Genetic modification of the host biosynthesis pathway

Altering the endogenous host N-glycosylation pathway could either reduce or completely remove fucose from antibody Fc. In a landmark study by Umana and colleagues, it was discovered that overexpressing the GnTIII enzyme, which catalyses the addition of bisecting GlcNAc, in CHO cells led to the production of recombinant IgG1 mAb with significantly reduced core fucosylation, associated with higher ADCC in vitro⁵⁸. The technology based on this GnTIII overexpression for generating low fucose therapeutics is referred to as GlycoMab, which was acquired by Roche⁵⁹. The addition of bisecting GlcNAc to Fc glycan by GnTIII pre-empts the downstream action of the α1,6-fucosyltransferase; thus, bisecting GlcNAc acts as a competitive inhibitor of core fucosylation and overexpression of GnTIII in mammalian cells provides a means of producing IgG with low fucose⁶⁰. To further diminish the fucose level, the same group engineered a recombinant form of GnTIII, which possesses the localization motif of the Golgi α-mannosidase II, whose overexpression gave rise to approximately 60-70% afucosylated complex and hybrid type glycans⁶¹. As we will discuss later, this GnTIII-engineered platform forms the basis of producing obinutuzumab, the recently approved anti-CD20 mAb used for the treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). While the impact of bisecting GlcNAc predominantly impacts ADCC through its inhibitory effect on core fucosylation, there are some indications that GlcNAc might modulate receptor affinity independent of this effect⁶².

Although the overexpression of GnTIII in a cell line leads to reduced levels of fucose, this is not complete and there remains significant room for improvement, i.e. complete defucosylation. One means of achieving this involves genetically disabling the α1,6-fucosyltransferase encoded by the *FUT8* gene. Just such a *FUT8* knock-out (KO) cell line was generated in CHO cells via homologous recombination, and lead to the production of 100% afucosylated antibodies⁶³. This *FUT8* KO antibody production platform was coined Potelligent technology, and was the system used to develop the anti-Cysteine-Cysteine chemokine receptor 4 (CCR4) mAb, mogamulizumab, the first approved glyco-engineered antibody⁶⁴ (see Section 4.1). Another means of dampening α1,6-

fucosyltransferase activity involves siRNA targeting of *FUT8*. Unfortunately, these reagents are not highly efficient, reducing *FUT8* transcription by only 20% resulting in approximately 60% afucosylated IgG ⁶⁵.

Apart from a direct *FUT8* gene KO, a second approach involves interfering with the GDP-fucose de novo biosynthesis pathway, whose resulting substrate GDP-fucose is essential for routinely cultured cells to produce fucosylated glycoproteins. One target enzyme in the pathway, the GDP-mannose 4,6-dehydratase (GMD), is involved in the catalytic process of converting D-glucose to GDP-fucose, the substrate of α 1,6-fucosyltransferase that is indispensable for IgG core fucosylation ⁶⁶. CHO cells deficient in the GMD gene showed a complete lack of GDP-fucose, and in the absence of exogenous L-fucose produced 100% afucosylated IgG ⁶⁷. Yet another means of interfering with GMD activity involves the heterologous expression of the GDP-6-deoxy-D-lyxo-4-hexulose reductase (RMD). RMD catalyses the production of monosaccharide GDP-D-rhamnose which provides feedback inhibition to GMD activity ⁶⁸, resulting in less GDP-fucose production and lowered antibody fucosylation ⁶⁹. The introduction of heterologous RMD produced a surprisingly high (98%) level of afucosylated IgG, reflecting the potency of this feedback inhibition pathway ⁶⁹. The technology based on this heterologous induction of RMD is referred to as GlymaxX developed by the company ProBioGen.

The above-mentioned glyco-engineering methods, notably carried out in CHO cells, produce the most mammalian-like IgG glycoforms comprising mostly biantennary complex type glycans. Oligosaccharides early in the N-glycosylation pathway intrinsically lack core fucose, as the α 1,6-fucosyltransferase only acts from the mid-phase of the N-glycosylation pathway with the target glycans becoming more favoured substrates following the action of GnTI ⁷⁰. Therefore, retaining the oligosaccharide in its early immature form, prior to GnTI action, should enable the production of relatively homogenous afucosylated glycoforms. Indeed, the HEK293S cell line, which is engineered to be deficient in the GnTI enzyme required for oligosaccharide maturation, is commonly used to produce afucosylated oligomannose glycoforms ⁷¹⁻⁷². However, despite homogeneous afucosylation, the predominance of the oligomannose antibody glycoforms produced deviates significantly in composition from the endogenous biantennary complex type glycoforms ⁷³, triggering debates over its perceived inferior in vivo pharmacokinetics ⁷⁴⁻⁷⁶. On balance, it seems that oligomannose-type glycoforms of IgG do exhibit more rapid serum clearance presumably driven by lectin-mediated clearance pathways ⁷⁵. Nonetheless, this HEK293S cell line remains a useful glyco-engineering tool in the laboratory.

Besides mammalian cells, other eukaryotic systems have been engineered to produce low fucose antibodies. For example, the yeast *Pichia pastoris* has been extensively engineered to produce both homogeneous fucosylated and non-fucosylated glycoforms ⁷⁷. More recently, the unicellular ciliate, *Tetrahymena thermophila*, has been reported to generate highly afucoylated mAbs with the advantageous ease of production ⁷⁸. Furthermore, the plant *Lemna minor*, when transfected with siRNA to suppress its intrinsic α 1,3-fucosyltransferase and β 1,2-xylosyltransferase activity, was able to generate 96% afucosylated, di-galactosylated glycoforms ⁷⁹. Notwithstanding the versatility of such non-mammalian systems, the existence of non-self carbohydrate epitopes, even in minute amount, has generally been considered a source of concern for their clinical use.

3.2 Metabolic interference of host biosynthesis pathway

Genetic modification of cellular systems usually requires significant investment, both temporal and financial. There are also substantial regulatory hurdles to pass before new cell lines are approved for the production of

clinical grade material. Metabolic interference, which employs soluble enzyme inhibitors, potentially provides an alternative to the generation of new cell lines and is especially useful in preclinical laboratory settings where proof of concept takes priority. One molecule, kifunensine, an alkaloid inhibitor of the α 1,2-mannosidase I enzyme, prevents the mannose trimming of the initial oligosaccharide and thus retains the N-glycan in its early afucosylated oligomannose form ⁸⁰⁻⁸¹. Moreover, synthetic inhibitors (such as 2-fluorofucose) based on the structure of metabolic intermediates of the GDP-fucose de novo synthesis pathway were shown to elicit 95% afucosylated glycoforms in CHO cells ⁸². However, compared with genetically modified host cell lines, inhibitor-based metabolic interference can prove impractical when production is scaled up for clinical use.

3.3 Post-translational enzymatic modification

An alternative strategy involves employing post-translational modification. Rapid advancement in chemical biology has expanded the set of synthetic tools available for post-translational glycan modification. In recent years, chemoenzymatic glyco-engineering has emerged as a reliable method for generating homogeneously glycosylated antibodies. In vitro enzymatic or chemoenzymatic glyco-engineering involves serial enzymatic treatments of purified antibodies to achieve the desired glycoform, which offers the potential to produce both diverse yet homogeneous glycoforms. For example, the serial treatment of IgG with recombinant galactosyltransferase and sialyltransferase coupled with their respective substrate is able to generate tetra-sialylated antibodies with an anti-inflammatory effect ⁴¹. However, much work still remains to do in this field as certain enzymatic reactions, such as defucosylation, within the N-glycosylation pathway, cannot yet readily be reproduced in this manner on natively folded antibodies with the full biantennary complex glycans ⁸³.

Therefore, transglycosylation, a method in which the bulk Fc oligosaccharide is first removed followed by the addition of pre-synthesized glycans of the desired structure, was developed to bypass some inefficient glycosyltransferases and glycosidases in the N-glycosylation pathway. The first-generation transglycosylation was pioneered by the Wang group that uses EndoH to deglycosylate the bulk oligomannose Fc glycan, followed by the addition of synthetic small biantennary glycans back onto the same glycosylation site using the glycosyltransferase EndoA to generate fully afucosylated Fc glycoforms ⁶². However, EndoA lacks the ability to transglycosylate the typical full length complex type glycans, which prompted the engineering of another bacterial glycosidase EndoS. EndoS usually deglycosylates Fc glycan but when mutated could be converted into a versatile Fc-specific trans-glycosyltransferase ⁸³. Indeed, the serial application of wild type EndoS to first remove the bulk Fc glycan and the fucosidase to remove any Fc core fucose, followed by the mutated EndoS (trans-glycosyltransferase) for the addition of fully afucosylated glycan, generated a human-like afucosylated Fc glycoform ⁸³. It is important that glycans pre-synthesized for transglycosylation in vitro do not undergo autocatalysis such as epimerization, which has been reported to contribute to heterogeneity ⁸⁴. Thus, chemoenzymatic glyco-engineering is an emerging route to generate fully afucosylated Fc glycoforms. However, this approach is likely to be advantageous over simple cell line or metabolic engineering mainly when particular synthetic challenges are faced, for example, when transglycosylation is employed to generate glycan-based antibody-drug conjugates ⁸⁵. Moreover, transglycosylation presents a significant challenge to cost-of-goods, and likely to be highly impractical as a manufacturing process unless it imparted critical functionality that could be obtained no other way.

4 Glyco-engineered antibodies in clinical oncology

Most antibodies approved for cancer therapy have demonstrated, to various extents, components of ADCC or ADCP in their therapeutic efficacy. Afucosylated antibody glycoforms uniquely exhibit enhanced Fc engagement with the activatory FcγRIIIa and FcγRIIIb resulting in more potent ADCC and ADCP⁵⁶⁻⁵⁸. Since the first definitive report of defucosylation-mediated ADCC enhancement in the early 2000s⁴⁴, two glyco-engineered, afucosylated, mAbs have already been approved for cancer therapies⁸⁶⁻⁸⁷. A list of fucose-engineered antibodies developed for clinical oncology are shown in Table 1.

It is important to note that while fucose-engineered mAbs gained most attention for cancer indications, various glycan-engineered mAbs are also being developed for other diseases. For example, roledumab, a low fucose anti-Rhesus D mAb, is currently in phaseII/III clinical trial to combat the hemolytic disease of the fetus or newborn^{6,88}. This section will focus on glyco-engineered antibodies for cancer treatment.

4.1 Mogamulizumab, the first approved glyco-engineered mAb

As detailed above, mogamulizumab, was the first approved (in Japan) glyco-engineered mAb for cancer therapy⁸⁹. Generated through the Potelligent technology, it is an afucosylated therapeutic targeting the chemokine receptor CCR4. CCR4 is normally expressed on CD4+ Th2 cells and some other T cell subsets but is also abundant on most adult T cell leukaemia lymphoma (ATLL) and cutaneous T-cell lymphomas (CTCL)^{86,90}. Mogamulizumab gained approval in 2012 for treatment of relapsed or refractory CCR4+ ATLL, and later in 2014 for treatment of relapsed or refractory CCR4+ CTCL⁸⁶. Preclinical studies indicate that mogamulizumab acts only through ADCC or ADCP, as no CDC or direct cell death were observed⁹¹. Moreover, mogamulizumab engagement of CCR4 is claimed not to induce CCR4 internalization, which might contribute to its favourable pharmacokinetics⁹². In addition, while various in vitro assays demonstrate the dominance of ADCC in mediating mogamulizumab efficacy, a non-glyco-engineered counterpart was not examined for comparison⁹¹.

4.2 Obinutuzumab and the anti-CD20 mAb family

CD20 represents one of the most studied tumour targets with 5 of the 26 currently approved anti-cancer mAbs targeting this same receptor. The approval of the rituximab in 1997 transformed the treatment of NHL and CLL^{3,93}, and paved the way for subsequent antibody therapeutics. Although various CD20-targeting mAbs followed suit into the clinic, the precise mechanism of action of anti-CD20 antibodies in the clinical setting remains debatable, partly due to the large amount of incongruous data generated over the years by different groups⁹⁴. In preclinical studies, both Fc-mediated ADCC, ADCP, CDC and Fab-mediated direct cell death were evident for various anti-CD20 mAbs⁹⁴. The current consensus indicates that the Fc domain, and in particular host activatory FcγRs, are required to recapitulate the clinical efficacy of anti-CD20¹²⁻¹³. The development of obinutuzumab, a low fucose anti-CD20 mAb approved in 2013 for treatment of CLL⁹⁴ and in 2016 for rituximab relapsed/refractory follicular lymphoma (FL)⁹⁵, was based on the premise that anti-CD20 mAb depletes malignant B cells through FcγRIIIa-mediated ADCC and/or ADCP⁹⁶⁻⁹⁸. Conceived from the GlycoMab platform, obinutuzumab was shown to mediate superior ADCC using human peripheral blood mononuclear cells as effectors to target CD20-expressing cell lines compared with the non-glyco-engineered obinutuzumab variant (i.e. with predominantly fucosylated

glycans), and rituximab, an observation recapitulated in xenograft tumour models ^{97, 99}. Interestingly, the same study reported similar in vitro ADCP activity for all anti-CD20 mAbs examined regardless of the level of fucosylation ^{56, 99}. In addition, obinutuzumab has been reported to exhibit increased neutrophil activation and phagocytosis through the neutrophil restricted activatory FcγRIIIb compared to rituximab ⁵⁶. This is perhaps unsurprising as FcγRIIIb is highly homologous to FcγRIIIa. The two genes likely arose through a gene duplication event and, despite their similarity, differences in antibody binding affinity and cellular distribution may imply their differential immunological roles ¹⁰⁰.

In 2014, data from a large phase III trial concluded that obinutuzumab in combination with chlorambucil gave more complete responses and improved progression free and overall survival compared with rituximab plus chlorambucil in patients with untreated CLL and coexisting conditions ^{87, 101-102}. Despite these conclusive clinical trial data, which many regard as a triumph for glyco-engineered anti-CD20 mAb therapy, questions remain over whether improvements conferred by obinutuzumab result from its low level of fucosylation, or from the fact that obinutuzumab is intrinsically a type II anti-CD20 mAb, a class of anti-CD20 antibodies associated with enhanced efficacy compared to type I anti-CD20 mAbs such as rituximab both in vitro and in multiple animal models ^{94, 103}. Type I and type II anti-CD20 mAbs differ in their mode of CD20 engagement and are typically characterised by their ability to redistribute cell surface CD20 molecules to lipid rafts, among other differences ^{97, 104-105}. More importantly, type II anti-CD20 mAbs are much less prone to internalization once bound to CD20 than type I mAbs, which are rapidly depleted from circulation ⁹⁹. This enhanced bioavailability of the type II obinutuzumab over the type I rituximab could contribute to the superiority of obinutuzumab in the trial, a hypothesis supported by a recent in vivo study demonstrating that the non-glyco-engineered, fucosylated form of obinutuzumab also outperforms rituximab in CLL clearance ¹⁰⁶.

4.3 Trastuzumab

Trastuzumab, commonly known as Herceptin, targets the Her2 molecule and was originally approved in 1998 for treatment of Her2 positive early stage breast cancer. Her2 is a cell surface receptor with tyrosine kinase activity, whose overexpression leads to constitutive signalling for cell survival ¹⁰⁷. Like rituximab, its precise mechanism of action remains unresolved. Although early reports suggested that trastuzumab acts by disrupting Her2 downstream signalling leading to apoptosis ¹⁰⁸⁻¹⁰⁹, recent studies implicate the importance of ADCC/ADCP in its efficacy ¹¹⁰. The clinical implication of the FcγR-mediated effector functions first emerged when one study found that patients treated with trastuzumab had better objective response rates when they possess the high affinity V/V 158 FcγRIIIa allotype compared with patients with the low affinity F/F or mixed V/F allotypes ¹¹¹. Consistently, PMBCs isolated from patients with the high affinity V/V 158 allotype exhibit enhanced ADCC against Her2 positive human breast cancer cell lines ¹¹¹. On the other hand, genetic polymorphisms within the FcγRIIB or FcγRIIA were not found to influence therapeutic outcomes ¹¹¹. This apparent association of superior therapeutic efficacy with high affinity FcγRIIIa engagement warrants Fc-engineering to further improve trastuzumab activity. Indeed, an afucosylated version of trastuzumab was produced using the *FUT8* KO CHO cell line, which exhibits an 11-fold enhancement in ADCC against the Her2-amplified BT474-M1 cell line compared with its non-glyco-engineered parent ¹¹². Furthermore, afucosylated trastuzumab significantly improved the survival of tumour-xenografted animals transgenic for the human FcγRIIIa compared with the non-glyco-engineered trastuzumab, an effect lost when the hFcγRIIIa is absent, further demonstrating the superior efficacy of an afucosylated

trastuzumab ¹¹². The enhanced ADCC observed in vitro and survival benefits in animal models warrant the continued clinical development of an afucosylated trastuzumab.

4.4 Afucosylated anti-EGFR GA201

EGFR is a receptor tyrosine kinase whose expression and activation are upregulated in diverse epithelial cancers. The anti-EGFR mAbs, cetuximab and panitumumab, represent established treatments for colorectal cancer and head and neck cancer, respectively; however, the overall response rate and survival benefits remain modest, with patients possessing KRAS mutations (of which a large proportion of these patients do) remaining unresponsive ¹¹³⁻¹¹⁴. Although anti-EGFR mAbs are purported to function through EGFR signalling blockade ¹¹⁵, it was hypothesized that their modest clinical efficacy might benefit from an engineered Fc. The low fucose anti-EGFR mAb GA201 was therefore generated using the GlycoMab technology and shown to be approximately 85% afucosylated ¹¹⁶. In vitro assays demonstrated that GA201 inhibits EGFR signal transduction to similar extent as cetuximab; however, afucosylation boosted the ADCC activity of GA201 significantly above that of cetuximab or the non-glyco-engineered GA201 ¹¹⁶. More importantly, GA201 exhibited ADCC activity towards tumour cell lines with KRAS mutations ¹¹⁶. The in vitro efficacy was recapitulated in xenograft animal models in which GA201 treatment led to prolonged survival compared with cetuximab regardless of the tumour KRAS mutation status ¹¹⁶. A phase I clinical trial also gave early demonstration of GA201 activity in EGFR positive solid tumours, including patients with KRAS mutations ¹¹⁷. Interestingly, FcγRIIIa polymorphism status did not influence the activity of GA201 in these patients, in contrast to those involved in the trastuzumab trial discussed earlier ^{111, 117}, potentially indicating that the glyco-engineering overcomes the lower activity associated with the low affinity allele, although this requires further confirmatory study in larger cohorts to confirm.

4.5 Anti-EphA3

Similar to EGFR, EphA3 is a receptor tyrosine kinase belonging to the family of Eph receptor tyrosine kinases involved in the regulation of cell-cell communication and development ¹¹⁸. Although there is no current anti-EphA3 mAb approved or indeed in late phase development, recently an afucosylated anti-EphA3 mAb, KB004, was reported to demonstrate modest efficacy in a phase I trial of relapsed and/or refractory hematologic malignancies ¹¹⁹⁻¹²⁰. The mechanism of action of KB004 remains unknown but presumably reflects those described above for EGFR mAbs.

4.6 Anti-CD19

CD19 is a ubiquitous marker expressed on B cells that associates with the BCR and acts to promote B cell activation. Due to its widespread expression on B cells, including early progenitors, CD19 has been assessed as a target for numerous B cell malignancies spanning ALL, CLL and NHL ¹²¹. Despite ubiquitous antigen expression, the efficacy of the conventional anti-CD19 mAbs developed so far indicates an inferiority to their anti-CD20 counterparts, with a notable lack of durable responses ¹²²⁻¹²³. Given their disappointing responses to date, antibody engineering has been attempted on these mAb to boost activity. To date, the only approved CD19-targeting biological therapeutic remains a bispecific anti-CD19/CD3 comprising two scFv chains, which acts to recruit CD3 positive T cells to exert cytotoxicity against B cells ¹²¹. In addition, multiple afucosylated anti-CD19 mAbs have been generated and are being clinically assessed. For example, MDX-1342, produced using the Potelligent technology, exhibits both enhanced ADCC and ADCP compared with its non-glyco-engineered

version, and was able to mediate a higher level of B cell depletion in non-human primates ¹²⁴⁻¹²⁵. A phase I trial of MDX-1342 to treat CD19-positive relapsed or refractory CLL demonstrated partial response in one of the nine patients recruited ¹²⁶⁻¹²⁷. MEDI-551 is another afucosylated anti-CD19 mAb, which similar to MDX-1342, exhibits more potent ADCC in vitro than its non-glyco-engineered parent as well as efficacy in multiple xenograft animal models ^{125, 128}. In a phase I/II clinical trial in patients with relapsed or refractory FL, diffuse large B-cell lymphoma, CLL, or multiple myeloma, MEDI-551 demonstrated moderate activity as a monotherapy ¹²⁹⁻¹³⁰. A third afucosylated mAb, DI-B4, has been transferred from Merck to Cancer Research UK as part of its Clinical Development Partnerships (CDP) programme, has recently been the subject of a Phase I trial in CD19 positive indolent B-cell lymphoma. No clinical results have been released yet.

4.7 Anti-CD30

CD30 belongs to the TNFR family involved in the regulation of cell survival. Its expression in normal tissues is restricted to activated B cells and T cells but it is highly expressed on T cell-derived tumours including anaplastic large-cell lymphoma and cutaneous T-cell lymphoma, making it a favourable tumour marker ¹³¹. Currently the only approved CD30-targeting antibody is Brentuximab Vedotin, an antibody-drug conjugate, whose efficacy stems from the cytotoxic agent monomethyl auristatin E ¹³². One anti-CD30 mAb, MDX-60, demonstrated modest efficacy against Hodgkin's lymphoma and anaplastic large-cell lymphoma in a phase I/II trial ¹³³. Its afucosylated version, MDX-1401, was subsequently developed using the Potelligent technology and improved survival in a xenograft animal model ¹³⁴. Moreover, in a phase I trial involving twelve refractory or relapsed HL patients, MDX-1401 treatment led to a reduction in tumour burden for patients experiencing stable disease ¹³⁵.

4.8 Anti-CD40

Like CD30, CD40 is a member of the TNFR family and has been extensively explored as a target for immunotherapy and anti-inflammatory applications ^{9, 136}. CD40 is ubiquitously expressed on various immune cells including B cells, macrophages, dendritic cells, as well as non-immune cells such as platelets and endothelial cells ¹³⁷. Although immunomodulatory (agonistic) anti-CD40 mAbs dominate the current focus for cancer research ⁹, some anti-CD40 mAbs were developed to target CD40-expressing B cell lymphomas as direct targeting mAbs: aiming to block positive signalling from, or even mediate inhibitory signalling through, CD40; or to mediate Fc-dependent cellular destruction. Currently, only one anti-CD40 mAb, SEA-CD40, has been developed as an afucosylated therapeutic directed at CD40, which exhibits enhanced ADCC in vitro compared with its fucosylated parent SGN40 ¹³⁸⁻¹³⁹. The development of SEA-CD40, however, is at odds with the apparent mechanism of action of its parent antibody, SGN40. SGN40 demonstrates modest clinical activity in CLL and diffuse large B-cell lymphoma ¹⁴⁰⁻¹⁴¹, but its in vivo efficacy, at least in one xenograft animal model, does not appear to require NK cell-mediated ADCC but rather depends on Fab-mediated apoptosis as full activity was demonstrated in mice lacking NK cells ¹⁴². Consistently, the clinical activity of SGN40 demonstrated in a phase II trial indicates a lack of correlation between patient FcγRIIIa 158 V/F polymorphism and therapeutic activity ¹⁴⁰. Nevertheless, the enhanced engagement between an afucosylated mAb and the FcγRIIIa provides the potential to overcome the in vivo threshold for SGN40-mediated ADCC and offer synergy with Fab-mediated apoptosis.

4.9 Anti-B-cell maturation antigen (BCMA)

The BCMA gene was originally identified from a translocation event in a malignant T cell lymphoma patient and was later found to be preferentially expressed on mature B cells¹⁴³⁻¹⁴⁴. It has since been established to be a member of the TNF receptor superfamily that interacts with B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) involved in B cell survival¹⁴⁵⁻¹⁴⁶. The ubiquitous expression of BCMA on multiple myeloma (MM) cells, but not on other normal human cell populations and tissues, renders BCMA a direct target for MM¹⁴⁷⁻¹⁴⁸. The first low fucose anti-BCMA mAb J6M0, humanized from a murine parent and fucose-engineered using the Potelligent platform, had an additional functional feature whereby the cytotoxic drug monomethyl auristatin (MMA), a synthetic inhibitor of cell division, is conjugated to its Fc domain¹⁴⁸. The Fc domain of such a low fucose antibody-drug conjugate (ADC) would be expected to not only induce enhanced cellular effector function via FcγRIIIA but also exert direct toxicity towards target tumor cells. Consistent with this hypothesis, J6M0-MMA mediated efficient *in vitro* phagocytosis of MM cells by macrophages and reduced the MM cell viability independent of immune effectors¹⁴⁸. Using immune-compromised animal models, the same group also reported superior *in vivo* efficacy of J6M0-MMA against human MM cell lines, compared with J6M0 alone¹⁴⁸. Nevertheless, the murine parent, nor a non-afucosylated variant, of J6M0 was not included in these experiments for comparison. While the MMA was covalently conjugated to the Fc protein backbone of J6M0, it is notable that with the coming of age of ADC, the unique chemistry of antibody Fc glycan (as opposed to the amino acid backbone) has been increasingly exploited as a site for cytotoxic drug conjugation¹⁴⁹⁻¹⁵⁵. The marriage between the intrinsic immune-modulatory properties of Fc glycan and its differential chemistry (from the protein backbone) could prove to be of great utility in the next generation cancer therapeutics.

5 Conclusion

In summary, it is clear that we are now entering an era when non-canonical antibody therapeutics are becoming commonplace. With recent advances in glyco-engineering we possess the tools to fine-tune the ability of the Fc to elicit the desired interactions with its potential receptors and interaction partners. The developments in afucosylation demonstrate a proof-of-principle that we can manipulate these interactions to elicit more efficacious responses from certain cellular effectors, potentially overcoming inter-patient variabilities in sub-optimal FcγR genotypes. However, the clinical experience illustrates that it is more important than ever that we fully understand the mechanisms of action of the parental mAbs *in vivo* before we undertake such studies – only then will the full potential of glyco-engineering be realised for patients.

Conflicts of Interest

MC is supported by a research grant from Against Breast Cancer (www.againstbreastcancer.org; UK charity number 1121258) and is the Against Breast Cancer Fellow at Oriel College, Oxford. MC was

founder and director of Immago Biosystems which was acquired by Hansa Medical. MM is supported by a BBSRC iCASE studentship in partnership with Roche. MSC acts as a consultant for Bioinvent International and has previously received research grant support from Roche, UCB and Promega, and has received honorarium from Baxalta. XY declares no conflicts of interest. No additional funding was received for the preparation of this review.

References

1. Maloney, D. G.; Grillo-Lopez, A. J.; White, C. A.; Bodkin, D.; Schilder, R. J.; Neidhart, J. A.; Janakiraman, N.; Foon, K. A.; Liles, T. M.; Dallaire, B. K.; Wey, K.; Royston, I.; Davis, T.; Levy, R., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* **1997**, *90* (6), 2188-95.
2. Casak, S. J.; Lemery, S. J.; Shen, Y. L.; Rothmann, M. D.; Khandelwal, A.; Zhao, H.; Davis, G.; Jarra, V.; Keegan, P.; Pazdur, R., U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. *Oncologist* **2011**, *16* (1), 97-104.
3. Molina, A., A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. *Annu Rev Med* **2008**, *59*, 237-50.
4. Scott, A. M.; Wolchok, J. D.; Old, L. J., Antibody therapy of cancer. *Nat Rev Cancer* **2012**, *12* (4), 278-87.
5. Guan, M.; Zhou, Y. P.; Sun, J. L.; Chen, S. C., Adverse events of monoclonal antibodies used for cancer therapy. *Biomed Res Int* **2015**, *2015*, 428169.
6. Reichert, J. M., Antibodies to watch in 2017. *MAbs* **2016**, 1-15.
7. Nimmerjahn, F.; Gordan, S.; Lux, A., FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. *Trends Immunol* **2015**, *36* (6), 325-36.
8. Lee, C. S.; Cragg, M.; Glennie, M.; Johnson, P., Novel antibodies targeting immune regulatory checkpoints for cancer therapy. *Br J Clin Pharmacol* **2013**, *76* (2), 233-47.
9. Vonderheide, R. H.; Glennie, M. J., Agonistic CD40 antibodies and cancer therapy. *Clin Cancer Res* **2013**, *19* (5), 1035-43.
10. Berman, D.; Korman, A.; Peck, R.; Feltquate, D.; Lonberg, N.; Canetta, R., The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. *Pharmacol Therapeut* **2015**, *148*, 132-153.
11. Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A. J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urban, W. J., Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* **2010**, *363* (8), 711-23.
12. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V., Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nature medicine* **2000**, *6* (4), 443-6.
13. Uchida, J.; Hamaguchi, Y.; Oliver, J. A.; Ravetch, J. V.; Poe, J. C.; Haas, K. M.; Tedder, T. F., The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. *The Journal of experimental medicine* **2004**, *199* (12), 1659-69.
14. White, A. L.; Chan, H. T.; Roghanian, A.; French, R. R.; Mockridge, C. I.; Tutt, A. L.; Dixon, S. V.; Ajona, D.; Verbeek, J. S.; Al-Shamkhani, A.; Cragg, M. S.; Beers, S. A.; Glennie, M. J., Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. *J Immunol* **2011**, *187* (4), 1754-63.

15. White, A. L.; Chan, H. T.; French, R. R.; Willoughby, J.; Mockridge, C. I.; Roghanian, A.; Penfold, C. A.; Booth, S. G.; Dodhy, A.; Polak, M. E.; Potter, E. A.; Ardern-Jones, M. R.; Verbeek, J. S.; Johnson, P. W.; Al-Shamkhani, A.; Cragg, M. S.; Beers, S. A.; Glennie, M. J., Conformation of the human immunoglobulin g2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. *Cancer cell* **2015**, 27 (1), 138-48.
16. Mekhaieel, D. N. A.; Czajkowsky, D. M.; Andersen, J. T.; Shi, J.; El-Faham, M.; Doenhoff, M.; McIntosh, R. S.; Sandlie, I.; He, J.; Hu, J.; Shao, Z.; Pleass, R. J., Polymeric human Fc-fusion proteins with modified effector functions. *Scientific Reports* **2011**, 1 (124).
17. Roghanian, A.; Teige, I.; Martensson, L.; Cox, K. L.; Kovacek, M.; Ljungars, A.; Mattson, J.; Sundberg, A.; Vaughan, A. T.; Shah, V.; Smyth, N. R.; Sheth, B.; Chan, H. T.; Li, Z. C.; Williams, E. L.; Manfredi, G.; Oldham, R. J.; Mockridge, C. I.; James, S. A.; Dahal, L. N.; Hussain, K.; Nilsson, B.; Verbeek, J. S.; Juliusson, G.; Hansson, M.; Jerkeman, M.; Johnson, P. W.; Davies, A.; Beers, S. A.; Glennie, M. J.; Frendeus, B.; Cragg, M. S., Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. *Cancer cell* **2015**, 27 (4), 473-88.
18. Li, F.; Ravetch, J. V., Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. *Science* **2011**, 333 (6045), 1030-4.
19. Lux, A.; Nimmerjahn, F., No Need for Constant Help: Human IgG2 Antibodies Have an Autonomous Agonistic Activity for Immunotherapy of Cancer. *Cancer cell* **2015**, 27 (1), 10-11.
20. Wilson, N. S.; Yang, B.; Yang, A.; Loeser, S.; Marsters, S.; Lawrence, D.; Li, Y.; Pitti, R.; Totpal, K.; Yee, S.; Ross, S.; Vernes, J. M.; Lu, Y.; Adams, C.; Offringa, R.; Kelley, B.; Hymowitz, S.; Daniel, D.; Meng, G.; Ashkenazi, A., An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. *Cancer cell* **2011**, 19 (1), 101-13.
21. Anderson, C. L.; Ganesan, L. P.; Robinson, J. M., The biology of the classical Fcγ receptors in non-hematopoietic cells. *Immunol Rev* **2015**, 268 (1), 236-40.
22. Nimmerjahn, F.; Ravetch, J. V., Fcγ receptors as regulators of immune responses. *Nat Rev Immunol* **2008**, 8 (1), 34-47.
23. Unkeless, J. C.; Jin, J., Inhibitory receptors, ITIM sequences and phosphatases. *Curr Opin Immunol* **1997**, 9 (3), 338-43.
24. Daeron, M., Fc receptor biology. *Annu Rev Immunol* **1997**, 15, 203-34.
25. Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. *Blood* **2012**, 119 (24), 5640-9.
26. Dahal, L. N.; Roghanian, A.; Beers, S. A.; Cragg, M. S., Fc gamma R requirements leading to successful immunotherapy. *Immunological Reviews* **2015**, 268 (1), 104-122.
27. Wu, J.; Edberg, J. C.; Redecha, P. B.; Bansal, V.; Guyre, P. M.; Coleman, K.; Salmon, J. E.; Kimberly, R. P., A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. *J Clin Invest* **1997**, 100 (5), 1059-70.
28. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood* **2002**, 99 (3), 754-8.
29. Shields, R. L.; Namenuk, A. K.; Hong, K.; Meng, Y. G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; Fox, J. A.; Presta, L. G., High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. *J Biol Chem* **2001**, 276 (9), 6591-604.
30. Preithner, S.; Elm, S.; Lippold, S.; Locher, M.; Wolf, A.; da Silva, A. J.; Baeuerle, P. A.; Prang, N. S., High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. *Molecular immunology* **2006**, 43 (8), 1183-93.
31. Baruah, K.; Bowden, T. A.; Krishna, B. A.; Dwek, R. A.; Crispin, M.; Scanlan, C. N., Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. *J Mol Biol* **2012**, 420 (1-2), 1-7.

32. Arnold, J. N.; Wormald, M. R.; Sim, R. B.; Rudd, P. M.; Dwek, R. A., The impact of glycosylation on the biological function and structure of human immunoglobulins. *Annu Rev Immunol* **2007**, *25*, 21-50.
33. Lund, J.; Takahashi, N.; Pound, J. D.; Goodall, M.; Jefferis, R., Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. *J Immunol* **1996**, *157* (11), 4963-9.
34. Walker, M. R.; Lund, J.; Thompson, K. M.; Jefferis, R., Aglycosylation of Human IgG1 and IgG3 Monoclonal-Antibodies Can Eliminate Recognition by Human-Cells Expressing Fc-Gamma-R1 and or Fc-Gamma-R2 Receptors. *Biochem J* **1989**, *259* (2), 347-353.
35. Jefferis, R.; Lund, J., Glycosylation of antibody molecules: structural and functional significance. *Chem Immunol* **1997**, *65*, 111-28.
36. Malhotra, R.; Wormald, M. R.; Rudd, P. M.; Fischer, P. B.; Dwek, R. A.; Sim, R. B., Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. *Nature medicine* **1995**, *1* (3), 237-43.
37. Rook, G. A.; Steele, J.; Brealey, R.; Whyte, A.; Isenberg, D.; Sumar, N.; Nelson, J. L.; Bodman, K. B.; Young, A.; Roitt, I. M.; et al., Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. *Journal of autoimmunity* **1991**, *4* (5), 779-94.
38. Alavi, A.; Arden, N.; Spector, T. D.; Axford, J. S., Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy. *J Rheumatol* **2000**, *27* (6), 1379-85.
39. van de Geijn, F. E.; Wuhrer, M.; Selman, M. H.; Willemsen, S. P.; de Man, Y. A.; Deelder, A. M.; Hazes, J. M.; Dolhain, R. J., Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. *Arthritis research & therapy* **2009**, *11* (6), R193.
40. Ackerman, M. E.; Crispin, M.; Yu, X.; Baruah, K.; Boesch, A. W.; Harvey, D. J.; Dugast, A. S.; Heizen, E. L.; Ercan, A.; Choi, I.; Streeck, H.; Nigrovic, P. A.; Bailey-Kellogg, C.; Scanlan, C.; Alter, G., Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. *J Clin Invest* **2013**, *123* (5), 2183-92.
41. Washburn, N.; Schwab, I.; Ortiz, D.; Bhatnagar, N.; Lansing, J. C.; Medeiros, A.; Tyler, S.; Mekala, D.; Cochran, E.; Sarvaiya, H.; Garofalo, K.; Meccariello, R.; Meador, J. W., 3rd; Rutitzky, L.; Schultes, B. C.; Ling, L.; Avery, W.; Nimmerjahn, F.; Manning, A. M.; Kaundinya, G. V.; Bosques, C. J., Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. *Proc Natl Acad Sci U S A* **2015**, *112* (11), E1297-306.
42. Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science* **2006**, *313* (5787), 670-3.
43. Li, T.; DiLillo, D. J.; Bournazos, S.; Giddens, J. P.; Ravetch, J. V.; Wang, L. X., Modulating IgG effector function by Fc glycan engineering. *Proc Natl Acad Sci U S A* **2017**, *114* (13), 3485-3490.
44. Shields, R. L.; Lai, J.; Keck, R.; O'Connell, L. Y.; Hong, K.; Meng, Y. G.; Weikert, S. H.; Presta, L. G., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. *J Biol Chem* **2002**, *277* (30), 26733-40.
45. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J Biol Chem* **2003**, *278* (5), 3466-73.
46. Niwa, R.; Natsume, A.; Uehara, A.; Wakitani, M.; Iida, S.; Uchida, K.; Satoh, M.; Shitara, K., IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. *J Immunol Methods* **2005**, *306* (1-2), 151-60.
47. Kanda, Y.; Yamane-Ohnuki, N.; Sakai, N.; Yamano, K.; Nakano, R.; Inoue, M.; Misaka, H.; Iida, S.; Wakitani, M.; Konno, Y.; Yano, K.; Shitara, K.; Hosoi, S.; Satoh, M., Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. *Biotechnology and bioengineering* **2006**, *94* (4), 680-8.

48. Ferrara, C.; Grau, S.; Jäger, C.; Sondermann, P.; Brünker, P.; Waldhauer, I.; Hennig, M.; Ruf, A.; Rufer, A. C.; Stihle, M.; Umaña, P.; Benz, J., Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. *Proceedings of the National Academy of Sciences* **2011**, *108* (31), 12669-12674.
49. Mizushima, T.; Yagi, H.; Takemoto, E.; Shibata-Koyama, M.; Isoda, Y.; Iida, S.; Masuda, K.; Satoh, M.; Kato, K., Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. *Genes Cells* **2011**, *16* (11), 1071-80.
50. Giulino, L. B.; Bussel, J. B.; Neufeld, E. J.; Pediatric; Platelet Immunology Committees of the, T. M. H. C. T. N., Treatment with rituximab in benign and malignant hematologic disorders in children. *J Pediatr* **2007**, *150* (4), 338-44, 344 e1.
51. Hosono, M.; Endo, K.; Sakahara, H.; Watanabe, Y.; Saga, T.; Nakai, T.; Kawai, C.; Matsumori, A.; Yamada, T.; Watanabe, T.; Konishi, J., Human Mouse Chimeric Antibodies Show Low Reactivity with Human Antimurine Antibodies (Hama). *Brit J Cancer* **1992**, *65* (2), 197-200.
52. Sheeley, D. M.; Merrill, B. M.; Taylor, L. C., Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. *Analytical biochemistry* **1997**, *247* (1), 102-10.
53. Qian, J.; Liu, T.; Yang, L.; Daus, A.; Crowley, R.; Zhou, Q., Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. *Analytical biochemistry* **2007**, *364* (1), 8-18.
54. Galili, U.; Rachmilewitz, E. A.; Peleg, A.; Flechner, I., A unique natural human IgG antibody with anti-alpha-galactosyl specificity. *The Journal of experimental medicine* **1984**, *160* (5), 1519-31.
55. Chung, C. H.; Mirakhur, B.; Chan, E.; Le, Q. T.; Berlin, J.; Morse, M.; Murphy, B. A.; Satinover, S. M.; Hosen, J.; Mauro, D.; Slebos, R. J.; Zhou, Q.; Gold, D.; Hatley, T.; Hicklin, D. J.; Platts-Mills, T. A., Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. *N Engl J Med* **2008**, *358* (11), 1109-17.
56. Golay, J.; Da Roit, F.; Bologna, L.; Ferrara, C.; Leusen, J. H.; Rambaldi, A.; Klein, C.; Introna, M., Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. *Blood* **2013**, *122* (20), 3482-3491.
57. Herter, S.; Birk, M. C.; Klein, C.; Gerdes, C.; Umana, P.; Bacac, M., Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity. *Journal of Immunology* **2014**, *192* (5), 2252-2260.
58. Umana, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J. E., Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. *Nat Biotechnol* **1999**, *17* (2), 176-80.
59. Evans, J. B.; Syed, B. A., From the analyst's couch: Next-generation antibodies. *Nat Rev Drug Discov* **2014**, *13* (6), 413-4.
60. Schachter, H., Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. *Biochem Cell Biol* **1986**, *64* (3), 163-81.
61. Ferrara, C.; Brunker, P.; Suter, T.; Moser, S.; Puntener, U.; Umana, P., Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. *Biotechnology and bioengineering* **2006**, *93* (5), 851-61.
62. Zou, G.; Ochiai, H.; Huang, W.; Yang, Q.; Li, C.; Wang, L. X., Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to Fcγ₃ receptor. *Journal of the American Chemical Society* **2011**, *133* (46), 18975-91.
63. Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; Shitara, K.; Satoh, M., Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated

antibodies with enhanced antibody-dependent cellular cytotoxicity. *Biotechnology and bioengineering* **2004**, 87 (5), 614-22.

64. Matsushita, T., Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent(R) Technology. *Korean J Hematol* **2011**, 46 (3), 148-50.

65. Mori, K.; Kuni-Kamochi, R.; Yamane-Ohnuki, N.; Wakitani, M.; Yamano, K.; Imai, H.; Kanda, Y.; Niwa, R.; Iida, S.; Uchida, K.; Shitara, K.; Satoh, M., Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. *Biotechnology and bioengineering* **2004**, 88 (7), 901-8.

66. Sullivan, F. X.; Kumar, R.; Kriz, R.; Stahl, M.; Xu, G. Y.; Rouse, J.; Chang, X. J.; Boodhoo, A.; Potvin, B.; Cumming, D. A., Molecular cloning of human GDP-mannose 4,6-dehydratase and reconstitution of GDP-fucose biosynthesis in vitro. *J Biol Chem* **1998**, 273 (14), 8193-202.

67. Kanda, Y.; Imai-Nishiya, H.; Kuni-Kamochi, R.; Mori, K.; Inoue, M.; Kitajima-Miyama, K.; Okazaki, A.; Iida, S.; Shitara, K.; Satoh, M., Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. *J Biotechnol* **2007**, 130 (3), 300-10.

68. King, J. D.; Poon, K. K.; Webb, N. A.; Anderson, E. M.; McNally, D. J.; Brisson, J. R.; Messner, P.; Garavito, R. M.; Lam, J. S., The structural basis for catalytic function of GMD and RMD, two closely related enzymes from the GDP-D-rhamnose biosynthesis pathway. *FEBS J* **2009**, 276 (10), 2686-700.

69. von Horsten, H. H.; Ogorek, C.; Blanchard, V.; Demmler, C.; Giese, C.; Winkler, K.; Kaup, M.; Berger, M.; Jordan, I.; Sandig, V., Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. *Glycobiology* **2010**, 20 (12), 1607-18.

70. Crispin, M.; Harvey, D. J.; Chang, V. T.; Yu, C.; Aricescu, A. R.; Jones, E. Y.; Davis, S. J.; Dwek, R. A.; Rudd, P. M., Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. *Glycobiology* **2006**, 16 (8), 748-56.

71. Reeves, P. J.; Callewaert, N.; Contreras, R.; Khorana, H. G., Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. *Proc Natl Acad Sci U S A* **2002**, 99 (21), 13419-24.

72. Yu, X.; Baruah, K.; Harvey, D. J.; Vasiljevic, S.; Alonzi, D. S.; Song, B. D.; Higgins, M. K.; Bowden, T. A.; Scanlan, C. N.; Crispin, M., Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. *Journal of the American Chemical Society* **2013**, 135 (26), 9723-32.

73. Yu, X.; Vasiljevic, S.; Mitchell, D. A.; Crispin, M.; Scanlan, C. N., Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. *J Mol Biol* **2013**, 425 (8), 1253-8.

74. Kanda, Y.; Yamada, T.; Mori, K.; Okazaki, A.; Inoue, M.; Kitajima-Miyama, K.; Kuni-Kamochi, R.; Nakano, R.; Yano, K.; Kakita, S.; Shitara, K.; Satoh, M., Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. *Glycobiology* **2007**, 17 (1), 104-18.

75. Goetze, A. M.; Liu, Y. D.; Zhang, Z.; Shah, B.; Lee, E.; Bondarenko, P. V.; Flynn, G. C., High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. *Glycobiology* **2011**, 21 (7), 949-59.

76. Millward, T. A.; Heitzmann, M.; Bill, K.; Langle, U.; Schumacher, P.; Forrer, K., Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. *Biologicals : journal of the International Association of Biological Standardization* **2008**, 36 (1), 41-7.

77. Li, H.; Sethuraman, N.; Stadheim, T. A.; Zha, D.; Prinz, B.; Ballew, N.; Bobrowicz, P.; Choi, B. K.; Cook, W. J.; Cukan, M.; Houston-Cummings, N. R.; Davidson, R.; Gong, B.; Hamilton, S. R.; Hoopes, J. P.; Jiang, Y.; Kim, N.; Mansfield, R.; Nett, J. H.; Rios, S.; Strawbridge, R.; Wildt, S.; Gerngross, T. U., Optimization of humanized IgGs in glycoengineered *Pichia pastoris*. *Nat Biotechnol* **2006**, 24 (2), 210-5.

78. Calow, J.; Behrens, A. J.; Mader, S.; Bockau, U.; Struwe, W. B.; Harvey, D. J.; Cormann, K. U.; Nowaczyk, M. M.; Loser, K.; Schinor, D.; Hartmann, M. W. W.; Crispin, M., Antibody production using

a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity. *Mabs* **2016**, 8 (8), 1498-1511.

79. Cox, K. M.; Sterling, J. D.; Regan, J. T.; Gasdaska, J. R.; Frantz, K. K.; Peele, C. G.; Black, A.; Passmore, D.; Moldovan-Loomis, C.; Srinivasan, M.; Cuisson, S.; Cardarelli, P. M.; Dickey, L. F., Glycan optimization of a human monoclonal antibody in the aquatic plant *Lemna minor*. *Nat Biotechnol* **2006**, 24 (12), 1591-7.

80. Elbein, A. D.; Tropea, J. E.; Mitchell, M.; Kaushal, G. P., Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. *J Biol Chem* **1990**, 265 (26), 15599-605.

81. Bowden, T. A.; Baruah, K.; Coles, C. H.; Harvey, D. J.; Yu, X.; Song, B. D.; Stuart, D. I.; Aricescu, A. R.; Scanlan, C. N.; Jones, E. Y.; Crispin, M., Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. *J Am Chem Soc* **2012**, 134 (42), 17554-63.

82. Okeley, N. M.; Alley, S. C.; Anderson, M. E.; Boursalian, T. E.; Burke, P. J.; Emmerton, K. M.; Jeffrey, S. C.; Klussman, K.; Law, C. L.; Sussman, D.; Toki, B. E.; Westendorf, L.; Zeng, W.; Zhang, X.; Benjamin, D. R.; Senter, P. D., Development of orally active inhibitors of protein and cellular fucosylation. *Proc Natl Acad Sci U S A* **2013**, 110 (14), 5404-9.

83. Huang, W.; Giddens, J.; Fan, S. Q.; Toonstra, C.; Wang, L. X., Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. *Journal of the American Chemical Society* **2012**, 134 (29), 12308-18.

84. Ahmed, A. A.; Giddens, J.; Pincetic, A.; Lomino, J. V.; Ravetch, J. V.; Wang, L. X.; Bjorkman, P. J., Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. *J Mol Biol* **2014**, 426 (18), 3166-79.

85. Parsons, T. B.; Struwe, W. B.; Gault, J.; Yamamoto, K.; Taylor, T. A.; Raj, R.; Wals, K.; Mohammed, S.; Robinson, C. V.; Benesch, J. L.; Davis, B. G., Optimal Synthetic Glycosylation of a Therapeutic Antibody. *Angew Chem Int Ed Engl* **2016**, 55 (7), 2361-7.

86. Duvic, M.; Evans, M.; Wang, C., Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. *Ther Adv Hematol* **2016**, 7 (3), 171-4.

87. Goede, V.; Fischer, K.; Busch, R.; Engelke, A.; Eichhorst, B.; Wendtner, C. M.; Chagorova, T.; de la Serna, J.; Dिल्huydy, M. S.; Illmer, T.; Opat, S.; Owen, C. J.; Samoylova, O.; Kreuzer, K. A.; Stilgenbauer, S.; Dohner, H.; Langerak, A. W.; Ritgen, M.; Kneba, M.; Asikanius, E.; Humphrey, K.; Wenger, M.; Hallek, M., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med* **2014**, 370 (12), 1101-10.

88. Yver, A.; Homery, M. C.; Fuseau, E.; Guemas, E.; Dhainaut, F.; Quagliaroli, D.; Beliard, R.; Prost, J. F., Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCgammaRIII, in healthy volunteers. *Vox Sang* **2012**, 103 (3), 213-22.

89. Subramaniam, J. M.; Whiteside, G.; McKeage, K.; Croxtall, J. C., Mogamulizumab: first global approval. *Drugs* **2012**, 72 (9), 1293-8.

90. Yoshie, O.; Matsushima, K., CCR4 and its ligands: from bench to bedside. *Int Immunol* **2015**, 27 (1), 11-20.

91. Ishii, T.; Ishida, T.; Utsunomiya, A.; Inagaki, A.; Yano, H.; Komatsu, H.; Iida, S.; Imada, K.; Uchiyama, T.; Akinaga, S.; Shitara, K.; Ueda, R., Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. *Clin Cancer Res* **2010**, 16 (5), 1520-31.

92. Duvic, M.; Pinter-Brown, L. C.; Foss, F. M.; Sokol, L.; Jorgensen, J. L.; Challagundla, P.; Dwyer, K. M.; Zhang, X.; Kurman, M. R.; Ballerini, R.; Liu, L.; Kim, Y. H., Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. *Blood* **2015**, 125 (12), 1883-9.

93. Oldham, R. K.; Dillman, R. O., Monoclonal antibodies in cancer therapy: 25 years of progress. *J Clin Oncol* **2008**, 26 (11), 1774-7.

94. Oldham, R. J.; Cleary, K. L. S.; Cragg, M. S., CD20 and Its Antibodies: Past, Present, and Future. *Forum on Immunopathological Diseases and Therapeutics* **2014**, 5 (1-2), 7-23.

95. Sehn, L. H.; Chua, N.; Mayer, J.; Dueck, G.; Trneny, M.; Bouabdallah, K.; Fowler, N.; Delwail, V.; Press, O.; Salles, G.; Gribben, J.; Lennard, A.; Lugtenburg, P. J.; Dimier, N.; Wassner-Fritsch, E.; Fingerle-Rowson, G.; Cheson, B. D., Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol* **2016**, *17* (8), 1081-93.
96. Cameron, F.; McCormack, P. L., Obinutuzumab: first global approval. *Drugs* **2014**, *74* (1), 147-54.
97. Mossner, E.; Brunker, P.; Moser, S.; Puntener, U.; Schmidt, C.; Herter, S.; Grau, R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; Ferrara, C.; Sondermann, P.; Jager, C.; Strein, P.; Fertig, G.; Friess, T.; Schull, C.; Bauer, S.; Dal Porto, J.; Del Nagro, C.; Dabbagh, K.; Dyer, M. J.; Poppema, S.; Klein, C.; Umana, P., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. *Blood* **2010**, *115* (22), 4393-402.
98. Herter, S.; Birk, M. C.; Klein, C.; Gerdes, C.; Umana, P.; Bacac, M., Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. *J Immunol* **2014**, *192* (5), 2252-60.
99. Herter, S.; Herting, F.; Mundigl, O.; Waldhauer, I.; Weinzierl, T.; Fauti, T.; Muth, G.; Ziegler-Landesberger, D.; Van Puijenbroek, E.; Lang, S.; Duong, M. N.; Reslan, L.; Gerdes, C. A.; Friess, T.; Baer, U.; Burtcher, H.; Weidner, M.; Dumontet, C.; Umana, P.; Niederfellner, G.; Bacac, M.; Klein, C., Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. *Mol Cancer Ther* **2013**, *12* (10), 2031-42.
100. Bournazos, S.; Woof, J. M.; Hart, S. P.; Dransfield, I., Functional and clinical consequences of Fc receptor polymorphic and copy number variants. *Clin Exp Immunol* **2009**, *157* (2), 244-54.
101. Goede, V.; Fischer, K.; Humphrey, K.; Asikanius, E.; Busch, R.; Engelke, A.; Wendtner, C. M.; Samoylova, O.; Chagorova, T.; Dilhuydy, M. S.; Torroba, J. D.; Illmer, T.; Opat, S.; Owen, C.; Kreuzer, K. A.; Langerak, A. W.; Ritgen, M.; Stilgenbauer, S.; Wenger, M.; Hallek, M., Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. *Journal of Clinical Oncology* **2013**, *31* (15).
102. Goede, V.; Fischer, K.; Busch, R.; Engelke, A.; Eichhorst, B.; Wendtner, C. M.; Chagorova, T.; De la Serna, J.; Dilhuydy, M. S.; Opat, S.; Owen, C. J.; Samoylova, O.; Kreuzer, K. A.; Langerak, A. W.; Ritgen, M.; Stilgenbauer, S.; Dohner, H.; Asikanius, E.; Humphrey, K.; Wenger, M. K.; Hallek, M., Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. *Blood* **2013**, *122* (21).
103. Klein, C.; Lammens, A.; Schafer, W.; Georges, G.; Schwaiger, M.; Mossner, E.; Hopfner, K. P.; Umana, P.; Niederfellner, G., Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. *MAbs* **2013**, *5* (1), 22-33.
104. Deans, J. P.; Robbins, S. M.; Polyak, M. J.; Savage, J. A., Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. *J Biol Chem* **1998**, *273* (1), 344-8.
105. Cragg, M. S.; Morgan, S. M.; Chan, H. T.; Morgan, B. P.; Filatov, A. V.; Johnson, P. W.; French, R. R.; Glennie, M. J., Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. *Blood* **2003**, *101* (3), 1045-52.
106. Tipton, T. R.; Roghanian, A.; Oldham, R. J.; Carter, M. J.; Cox, K. L.; Mockridge, C. I.; French, R. R.; Dahal, L. N.; Duriez, P. J.; Hargreaves, P. G.; Cragg, M. S.; Beers, S. A., Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. *Blood* **2015**, *125* (12), 1901-9.
107. Arteaga, C. L.; Sliwkowski, M. X.; Osborne, C. K.; Perez, E. A.; Puglisi, F.; Gianni, L., Treatment of HER2-positive breast cancer: current status and future perspectives. *Nat Rev Clin Oncol* **2011**, *9* (1), 16-32.

108. Junttila, T. T.; Akita, R. W.; Parsons, K.; Fields, C.; Phillips, G. D. L.; Friedman, L. S.; Sampath, D.; Sliwkowski, M. X., Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. *Cancer cell* **2009**, *15* (5), 429-440.
109. Yakes, F. M.; Chinratanalab, W.; Ritter, C. A.; King, W.; Seelig, S.; Arteaga, C. L., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. *Cancer Res* **2002**, *62* (14), 4132-41.
110. Listinsky, J. J.; Siegal, G. P.; Listinsky, C. M., Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model. *Anticancer Drugs* **2013**, *24* (3), 219-27.
111. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; Neri, T. M.; Ardizzoni, A., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. *J Clin Oncol* **2008**, *26* (11), 1789-96.
112. Junttila, T. T.; Parsons, K.; Olsson, C.; Lu, Y.; Xin, Y.; Theriault, J.; Crocker, L.; Pabonan, O.; Baginski, T.; Meng, G.; Totpal, K.; Kelley, R. F.; Sliwkowski, M. X., Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. *Cancer Res* **2010**, *70* (11), 4481-9.
113. Amado, R. G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D. J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S. D.; Chang, D. D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *Journal of Clinical Oncology* **2008**, *26* (10), 1626-1634.
114. Lievre, A.; Bachet, J. B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J. F.; Cote, J. F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Research* **2006**, *66* (8), 3992-3995.
115. Goldstein, N. I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J., Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. *Clin Cancer Res* **1995**, *1* (11), 1311-8.
116. Gerdes, C. A.; Nicolini, V. G.; Herter, S.; van Puijenbroek, E.; Lang, S.; Roemmele, M.; Moessner, E.; Freytag, O.; Friess, T.; Ries, C. H.; Bossenmaier, B.; Mueller, H. J.; Umana, P., GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. *Clin Cancer Res* **2013**, *19* (5), 1126-38.
117. Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J. P.; Cervantes, A.; Markman, B.; Corral, J.; Soria, J. C.; Berge, Y.; Roda, D.; Russell-Yarde, F.; Hollingsworth, S.; Baselga, J.; Umana, P.; Manenti, L.; Tabernero, J., Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. *J Clin Oncol* **2011**, *29* (28), 3783-90.
118. Poliakov, A.; Cotrina, M.; Wilkinson, D. G., Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. *Dev Cell* **2004**, *7* (4), 465-80.
119. Swords, R. T.; Greenberg, P. L.; Wei, A. H.; Durrant, S.; Advani, A. S.; Hertzberg, M. S.; Lewis, I. D.; Rivera, G.; Gratzinger, D.; Fan, A. C.; Felsher, D. W.; Cortes, J. E.; Watts, J. M.; Yarranton, G. T.; Walling, J. M.; Lancet, J. E., KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. *Leuk Res* **2016**, *50*, 123-131.
120. Swords, R. T.; Wei, A. H.; Durrant, S.; Advani, A. S.; Hertzberg, M. S.; Lewis, I. D.; Greenberg, P. L.; Cortes, J. E.; Yarranton, G. T.; Walling, J. M.; Lancet, J. E., KB004, a Novel Non-Fucosylated Humanized (R) Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies. *Blood* **2014**, *124* (21).
121. Naddafi, F.; Davami, F., Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy. *Int J Mol Cell Med* **2015**, *4* (3), 143-51.
122. Vlasveld, L. T.; Hekman, A.; Vythdreese, F. A.; Melief, C. J. M.; Sein, J. J.; Voordouw, A. C.; Dellemijn, T. A. M.; Rankin, E. M., Treatment of Low-Grade Non-Hodgkins-Lymphoma with

Continuous-Infusion of Low-Dose Recombinant Interleukin-2 in Combination with the B-Cell-Specific Monoclonal-Antibody Clb-Cd19. *Cancer Immunol Immun* **1995**, *40* (1), 37-47.

123. Hekman, A.; Honselaar, A.; Vuist, W. M.; Sein, J. J.; Rodenhuis, S.; ten Bokkel Huinink, W. W.; Somers, R.; Rumke, P.; Melief, C. J., Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. *Cancer Immunol Immunother* **1991**, *32* (6), 364-72.

124. Cardarelli, P. M.; Rao-Naik, C.; Chen, S.; Huang, H.; Pham, A.; Moldovan-Loomis, M. C.; Pan, C.; Preston, B.; Passmore, D.; Liu, J.; Kuhne, M. R.; Witte, A.; Blanset, D.; King, D. J., A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. *Cancer Immunol Immunother* **2010**, *59* (2), 257-65.

125. Herbst, R.; Wang, Y.; Gallagher, S.; Mittereder, N.; Kuta, E.; Damschroder, M.; Woods, R.; Rowe, D. C.; Cheng, L.; Cook, K.; Evans, K.; Sims, G. P.; Pfarr, D. S.; Bowen, M. A.; Dall'Acqua, W.; Shlomchik, M.; Tedder, T. F.; Kiener, P.; Jallal, B.; Wu, H.; Coyle, A. J., B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. *The Journal of pharmacology and experimental therapeutics* **2010**, *335* (1), 213-22.

126. Camacho, L. H.; Joyce, R.; Brown, J. R.; Chanan-Khan, A.; Amrein, P. C.; Assad, A.; Carrigan, M., A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia. *Blood* **2009**, *114* (22), 1330-1330.

127. Hammer, O., CD19 as an attractive target for antibody-based therapy. *Mabs* **2012**, *4* (5), 571-577.

128. Ward, E.; Mittereder, N.; Kuta, E.; Sims, G. P.; Bowen, M. A.; Dall'Acqua, W.; Tedder, T.; Kiener, P.; Coyle, A. J.; Wu, H.; Jallal, B.; Herbst, R., A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. *Br J Haematol* **2011**, *155* (4), 426-37.

129. Hamadani, M.; Forero, A.; Kipps, T. J.; Fanale, M. A.; Cuneo, A.; de Oteyza, J. P.; Gladstone, D.; Goswami, T.; Ibrahim, R. A.; Liang, M. N.; Eck, S.; Elgeioushi, N.; Herbst, R.; Cheson, B. D., MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab. *Journal of Clinical Oncology* **2013**, *31* (15).

130. Goswami, T.; Forero, A.; Hamadani, M.; Sonet, A.; Verhoef, G.; Fanale, M. A.; Bello, C. M.; Huang, W. M.; Cheson, B. D., Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. *Journal of Clinical Oncology* **2012**, *30* (15).

131. Senter, P. D.; Sievers, E. L., The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. *Nat Biotechnol* **2012**, *30* (7), 631-7.

132. Younes, A.; Bartlett, N. L.; Leonard, J. P.; Kennedy, D. A.; Lynch, C. M.; Sievers, E. L.; Forero-Torres, A., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med* **2010**, *363* (19), 1812-21.

133. Ansell, S. M.; Horwitz, S. M.; Engert, A.; Khan, K. D.; Lin, T.; Strair, R.; Keler, T.; Graziano, R.; Blanset, D.; Yellin, M.; Fischkoff, S.; Assad, A.; Borchmann, P., Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. *J Clin Oncol* **2007**, *25* (19), 2764-9.

134. Cardarelli, P. M.; Moldovan-Loomis, M. C.; Preston, B.; Black, A.; Passmore, D.; Chen, T. H.; Chen, S.; Liu, J.; Kuhne, M. R.; Srinivasan, M.; Assad, A.; Witte, A.; Graziano, R. F.; King, D. J., In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. *Clin Cancer Res* **2009**, *15* (10), 3376-83.

135. Thertulien, R.; Frankel, A.; Evens, A.; Kaufman, J.; Horwitz, S.; Assad, A.; Cardarelli, P.; Tian, J.; Zhang, Z. S.; MacDowall, M., A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma. *Cancer Research* **2009**, *69*.

136. Watanabe, M.; Yamashita, K.; Suzuki, T.; Kamachi, H.; Kuraya, D.; Koshizuka, Y.; Ogura, M.; Yoshida, T.; Aoyagi, T.; Fukumori, D.; Shimamura, T.; Okimura, K.; Maeta, K.; Miura, T.; Sakai, F.; Todo, S., ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. *Am J Transplant* **2013**, *13* (8), 1976-88.
137. Elgueta, R.; Benson, M. J.; de Vries, V. C.; Wasiuk, A.; Guo, Y.; Noelle, R. J., Molecular mechanism and function of CD40/CD40L engagement in the immune system. *Immunol Rev* **2009**, *229* (1), 152-72.
138. Gardai, S. J.; Epp, A.; Linares, G.; Westendorf, L.; Sutherland, M. K.; Neff-LaFord, H.; Drachman, J. G.; Peng, S.; Law, C. L., A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors. *Journal of Clinical Oncology* **2015**, *33* (15).
139. Gardai, S. J.; Epp, A.; Linares, G.; Westendorf, L.; Sutherland, M.; Neff-LaFord, H.; Peng, S. L.; Law, C. L., SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities. *Cancer Research* **2015**, *75*.
140. de Vos, S.; Forero-Torres, A.; Ansell, S. M.; Kahl, B.; Cheson, B. D.; Bartlett, N. L.; Furman, R. R.; Winter, J. N.; Kaplan, H.; Timmerman, J.; Whiting, N. C.; Drachman, J. G.; Advani, R., A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. *J Hematol Oncol* **2014**, *7*, 44.
141. Furman, R. R.; Forero-Torres, A.; Shustov, A.; Drachman, J. G., A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. *Leukemia Lymphoma* **2010**, *51* (2), 228-235.
142. Law, C. L.; Gordon, K. A.; Collier, J.; Klussman, K.; McEarchern, J. A.; Cervený, C. G.; Mixan, B. J.; Lee, W. P.; Lin, Z.; Valdez, P.; Wahl, A. F.; Grewal, I. S., Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. *Cancer Res* **2005**, *65* (18), 8331-8.
143. Laabi, Y.; Gras, M. P.; Brouet, J. C.; Berger, R.; Larsen, C. J.; Tsapis, A., The Bcma Gene, Preferentially Expressed during B-Lymphoid Maturation, Is Bidirectionally Transcribed. *Nucleic Acids Res* **1994**, *22* (7), 1147-1154.
144. Laabi, Y.; Gras, M. P.; Carbonnel, F.; Brouet, J. C.; Berger, R.; Larsen, C. J.; Tsapis, A., A New Gene, Bcm, on Chromosome-16 Is Fused to the Interleukin-2 Gene by a T(4-16)(Q26-P13) Translocation in a Malignant T-Cell Lymphoma. *Embo J* **1992**, *11* (11), 3897-3904.
145. MacLennan, I.; Vinuesa, C., Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. *Immunity* **2002**, *17* (3), 235-8.
146. O'Connor, B. P.; Raman, V. S.; Erickson, L. D.; Cook, W. J.; Weaver, L. K.; Ahonen, C.; Lin, L. L.; Mantchev, G. T.; Bram, R. J.; Noelle, R. J., BCMA is essential for the survival of long-lived bone marrow plasma cells. *Journal of Experimental Medicine* **2004**, *199* (1), 91-97.
147. Carpenter, R. O.; Evbuomwan, M. O.; Pittaluga, S.; Rose, J. J.; Raffeld, M.; Yang, S. C.; Gress, R. E.; Hakim, F. T.; Kochenderfer, J. N., B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma. *Clinical Cancer Research* **2013**, *19* (8), 2048-2060.
148. Tai, Y. T.; Mayes, P. A.; Acharya, C.; Zhong, M. Y.; Cea, M.; Cagnetta, A.; Craig, J.; Yates, J.; Gliddon, L.; Fieles, W.; Hoang, B.; Tunstead, J.; Christie, A. L.; Kung, A. L.; Richardson, P.; Munshi, N. C.; Anderson, K. C., Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood* **2014**, *123* (20), 3128-3138.
149. van Geel, R.; Wijdeven, M. A.; Heesbeen, R.; Verkade, J. M. M.; Wasil, A. A.; van Berkel, S. S.; van Delft, F. L., Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. *Bioconjugate Chem* **2015**, *26* (11), 2233-2242.
150. Qasba, P. K., Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases. *Bioconjugate Chem* **2015**, *26* (11), 2170-2175.
151. Li, X.; Fang, T.; Boons, G. J., Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. *Angew Chem Int Ed Engl* **2014**, *53* (28), 7179-82.

152. Zhou, Q.; Stefano, J. E.; Manning, C.; Kyazike, J.; Chen, B.; Gianolio, D. A.; Park, A.; Busch, M.; Bird, J.; Zheng, X. Y.; Simonds-Mannes, H.; Kim, J.; Gregory, R. C.; Miller, R. J.; Brondyk, W. H.; Dhal, P. K.; Pan, C. Q., Site-Specific Antibody-Drug Conjugation through Glycoengineering. *Bioconjugate Chem* **2014**, 25 (3), 510-520.
153. Zuberbuhler, K.; Casi, G.; Bernardes, G. J.; Neri, D., Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. *Chem Commun (Camb)* **2012**, 48 (56), 7100-2.
154. Beck, A.; Goetsch, L.; Dumontet, C.; Corvaia, N., Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov* **2017**.
155. Largy, E.; Cantais, F.; Van Vyncht, G.; Beck, A.; Delobel, A., Orthogonal LC/MS methods for the comprehensive characterization of therapeutic glycoproteins, from released glycans to intact protein level. *J Chromatogr A* **2017**.
156. Ishida, T.; Joh, T.; Uike, N.; Yamamoto, K.; Utsunomiya, A.; Yoshida, S.; Saburi, Y.; Miyamoto, T.; Takemoto, S.; Suzushima, H.; Tsukasaki, K.; Nosaka, K.; Fujiwara, H.; Ishitsuka, K.; Inagaki, H.; Ogura, M.; Akinaga, S.; Tomonaga, M.; Tobinai, K.; Ueda, R., Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. *J Clin Oncol* **2012**, 30 (8), 837-42.
157. Duvic, M.; Pinter-Brown, L.; Foss, F. M.; Sokol, L.; Jorgensen, J.; Spitalny, G. L.; Kim, Y. H., Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients. *Blood* **2010**, 116 (21), 424-424.
158. Gladstone, D.; Andre, M.; Jan, Z. C.; Assouline, S.; Bellam, N.; Cascavilla, N.; Jourdan, E.; Panwalkar, A.; Patti, C.; Schulte, C.; Zaja, F.; Goswami, T.; Elgeioushi, N.; Streicher, K.; Bao, H. F.; Spaner, D., Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia. *Blood* **2014**, 124 (21).
159. Forero-Torres, A.; Hamadani, M.; Fanale, M. A.; Bello, C. M.; Kipps, T. J.; Offner, F.; Verhoef, G.; Federico, M.; Gregory, S. A.; Sonet, A.; Assouline, S.; de Oteyza, J. P.; Tomas, J. F.; Cuneo, A.; Elgeioushi, N.; Goswami, T.; Ibrahim, R.; Herbst, R.; Cheson, B. D., Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. *Blood* **2013**, 122 (21).

FIGURE LEGEND

Figure 1. Structural basis of afucosylation-mediated enhancement of IgG receptor interaction. Crystal structures of fucosylated and afucosylated IgG1 Fc in complex with FcγRIIIa containing a glycan at Asn162 reported by Ferrara *et al.*⁴⁸. The FcγRIIIa component is shown in orange with transparent surface representation and cartoon representation of the protein chain. The FcγRIIIa glycan at Asn162 is shown in either red or green respectively for the structure containing Fc fucose and that without Fc fucose. The Fc protein is shown in grey with transparent surface and cartoon representation of the protein chain. Fc glycans are shown as sticks. The steric clash between the receptor glycan and the Fc fucose is highlighted by cartoon clash symbols.

Table 1- List of fucose-engineered mAbs for cancer treatment.

mAb name	Target	Modification	Technology	Condition	Phase	Results
mogamulizumab	CCR4	afucosylated	Potelligent	ATLL, CTCL	Approved	In relapsed CCR4+ ATLL, ORR was 50%, 8 CRs, $n = 26$. Ref ¹⁵⁶ . In CTCL, ORR was 39%, 13 PRs $n = 38$. Ref ¹⁵⁷ .
obinutuzumab	CD20	low fucose	GlycoMab	CLL, follicular lymphoma	Approved	In CLL, obinutuzumab + chlorambucil increased PFS to 26.7 months vs 16.3 months with rituximab + chlorambucil, $n = 781$. Ref ⁸⁷ . In rituximab-refractory indolent NHL, obinutuzumab plus bendamustine increased PFS to 22.5 months compared with 14.9 months by bendamustine monotherapy, $n = 396$. Ref ⁹⁵ .
*trastuzumab	Her2	afucosylated	<i>FUT8</i> KO CHO	ND	Preclinical	ND
GA201	EGFR	low fucose	GlycoMab	EGFR positive solid tumours	Phase I	1 CR and 2 PRs in observed colorectal cancer patients, disease stabilisation observed in 27 patients, $n = 75$. Ref ¹¹⁷ .
KB004	EphA3	afucosylated	ND	Advanced hematologic malignancies	Phase I	3 AML patients achieved clearance of bone marrow blasts, 3 patients with myelodysplastic syndrome achieved SDs ranging from 2-12 months, OR observed in 4 patients, $n = 64$. Ref ¹¹⁹ .
MDX-1342	CD19	afucosylated	Potelligent	relapsed or refractory CLL	Phase I	In CD19-positive relapsed or refractory CLL, 1 patient had PR, 6 had SD, 2 had DP, $n = 12$. Ref ¹²⁶ .
MEDI-551	CD19	afucosylated	Potelligent	Relapsed or refractory FL, DLBCL, CLL, MM	Phase I/II	In relapsed or refractory FL, DLBCL, CLL, MM, 3 patients experienced PRs and 2 CRs (lasted 9 months), $n = 25$. Ref ¹³⁰ . In refractory CLL, 4 had PR and 13 had SD, $n = 20$. Ref ¹²⁹ . In relapsed or refractory CLL, MEDI-551 + bendamustine demonstrated efficacy but results not further disclosed, $n = 147$. Ref ¹⁵⁸ . In CLL, DLBCL, FL and MM, 9 had CR, 12 had PR, 42 had SD, median PFS about 9 months, $n = 83$. Ref ¹⁵⁹ .
DI-B4	CD19	low fucose	ND	CD19 positive indolent B-cell lymphoma	Phase I	Results pending
MDX-1401	CD30	afucosylated	Potelligent	Refractory or relapsed HL	Phase I	In refractory or relapsed HL, 8 patients had SD (of which 2 had tumour burden reduction by at least 40%), 4 patients had DP, $n = 12$. Ref ¹³⁵ .
SEA-CD40	CD40	afucosylated	**Metabolic interference	Various advanced malignancies	Phase I	Patient recruitment in process

J6M0-mcMMAF	BCMA	afucosylated	Potelligent	MM	Preclinical	ND
-------------	------	--------------	-------------	----	-------------	----

*afucosylated trastuzumab

**this production method is inferred from related patents filed by Seattle Genetics, Inc., the company which developed SEA-40

Abbreviations: ORR- overall response rate; PFS- progression-free survival; CR- complete response; PR- partial response; OR- objective response; SD- stable disease; DP- disease progression; AML- acute myeloid leukaemia; MM- multiple myeloma; ND- not disclosed

